{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-033856","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2024-07-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.385394+00:00","generated_at":"2026-05-31T18:08:52.830234+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"BridgeBio appoints Thomas Trimarchi as President and COO; Neil Kumar remains CEO","bullets":["Thomas Trimarchi appointed President and COO effective July 23, 2024; Neil Kumar steps down as President but stays CEO and director.","Trimarchi previously served as Chief Product Officer since 2018; also board member of affiliate ML Bio Solutions (BBP-418 for LGMD2I/R9).","Newly created role to drive operational excellence, strategic planning, and centralize late-stage pipeline operations.","Trimarchi holds a Ph.D. in Molecular Oncology and Immunology from NYU; prior roles at Regeneron and Goldman Sachs."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-033856","json":"https://secwatch.observer/filing/0001140361-24-033856.json","markdown":"https://secwatch.observer/filing/0001140361-24-033856.md","text":"https://secwatch.observer/filing/0001140361-24-033856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036124033856/0001140361-24-033856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036124033856/ef20032871_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T18:08:52.830234+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b3923afd27","claim":"Neil Kumar changed role as President at BridgeBio Pharma, Inc..","evidence_excerpt":"Neil Kumar, Ph.D. stepped down as President","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000114036124033856/0001140361-24-033856-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"President"}]},{"claim_id":"d00a76d121","claim":"Thomas Trimarchi was appointed as President and Chief Operating Officer at BridgeBio Pharma, Inc..","evidence_excerpt":"Thomas Trimarchi was appointed as the Company’s President and Chief Operating Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000114036124033856/0001140361-24-033856-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Operating Officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}